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Introduction
Hypertension is a major independent cardiovascular 
risk factor, and also a marker of survival risk. Quality of 
life during the treatment of hypertension is an important 
health issue, as one in every five treated patients with 
hypertension will discontinue their therapy due to side-
effects.1  Discontinuation of therapy, and poor compliance 
with therapy, will eventually lead to a poorer outcome. The 
appearance of treatment-related side- effects may actually 
make patients feel worse than they did prior to treatment, 
when most hypertensive patients are asymptomatic.  Sexual 
dysfunction is a potential side-effect of therapy, and may 
lead to poor therapy compliance.
Sexual dysfunction
Sexual dysfunction is defined by the World Health 
Organization as the various ways in which an individual is 
unable to participate in a sexual relationship as desired.
Erectile dysfunction was formerly viewed as a psychological 
entity and dismissed as such, but currently, it is considered 
to be a disease of vascular origin.  Sexual dysfunction has 
been called: “the ‘prima ballerina’ of hypertension-related, 
quality-of-life complications”.2
Currently, erectile dysfunction is also considered to be an 
independent predictor of future cardiovascular disease, as 
it may be viewed as a manifestation of vascular dysfunction, 
and endothelial dysfunction underlies this symptom.
Sexual dysfunction in the general 
population
Erectile dysfunction, defined as the inability to have and 
maintain an erection that is adequate for intercourse, is 
increasingly more common with advancing age.  In a study 
of health professionals, erectile dysfunction occurred in 
four per cent of men under the age of 50, 27% in those 
between 50-59 years of age, and in 40% of men in the age 
group 60-69 years.3 The frequency was significantly higher 
if those men who were hypertensive, diabetic, smokers, or 
obese, or taking medications such as antidepressants and 
antihypertensives. The Massachusetts Male Ageing Study, 
the first longitudinal, community-based epidemiological 
study of 1 290 men, reported a prevalence of 52% of 
erectile dysfunction.4
Female sexual dysfunction is a much more complex 
situation, and remains understudied.  Female sexual 
dysfunction may be more prevalent than men: 43% vs. 31% 
as reported in 1999.5
Sexual dysfunction in patients with 
hypertension
The relationship between essential hypertension and 
sexual dysfunction raises the following question: is the 
hypertension the cause of the sexual dysfunction, or are the 
drugs that are used to treat hypertension, the cause?  This 
question remains only partially answered.2
Essential hypertension is widely accepted as a risk factor for 
erectile dysfunction. The relative risk of erectile dysfunction 
in hypertensive men vs. normotensives ranged from 1.3-
6.9.2  In a sample of 634 Greek men, erectile dysfunction 
was twice as common in hypertensives compared to 
normotensives (35.2% vs. 14.1%).2
Duration and severity of hypertension, as well as 
antihypertensive therapy, contribute to erectile dysfunction. 
Very little data exist on the role of smoking, alcohol intake, 
and level of physical activity, regarding erectile dysfunction 
in patients with essential hypertension. The little data that 
does exist on female hypertensives reveal that hypertension 
per se contributes to sexual dysfunction. A study suggested 
that there is sexual dysfunction in 42.1% of hypertensive 
women, compared to 19.4% in normotensive women. The 
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odds ratio of this is 3.2.2  Increasing systolic blood pressure, 
advancing age and beta-blocker use were significant 
predictors of sexual dysfunction in women.
Antihypertensive medication and sexual 
dysfunction
The old-generation type of antihypertensive drugs such as 
central acting beta blockers, e.g. methyldopa, and diuretics, 
can all negatively affect sexual function. The new-generation 
antihypertensives, including calcium-channel blockers and 
angiotensin-converting enzyme (ACE) inhibitors, seem to 
have a neutral effect.  
Angiotensin-receptor blockers may actually have a 
beneficial effect on sexual function.1 Beta-blocker use is 
associated with an increased risk of sexual dysfunction, and 
this even extends to some, though not all, of the newer-type 
beta blockers, but precise data on this are lacking.
Diuretics, including spironolactone, are one of the most 
implicated classes in sexual dysfunction, even when used 
as adjunct therapy. There are remarkably very little data on 
combination antihypertensive therapy which is problematic, 
as the majority of patients will eventually have to take 
combination therapy.
Phosphodiesterase-5 inhibitors
Phosphodiesterase-5 (PDE-5) inhibitors are effective for 
treating erectile dysfunction. Usually, use of these drugs 
leads to clinically insignificant reductions in blood pressure, 
but it can have deleterious effects on patients taking 
complicated, multidrug antihypertensive regimens. For the 
majority of such patients, the blood pressure reduction will 
be minimal, and quite safe. The use of alpha-blockers may 
lead to a significant interaction with PDE-5 inhibitors, while 
that of organic nitratres, either short-acting, or long-acting in 
patients with ischaemic heart disease, is a contraindication 
for the use of PDE-5 inhibitors.
Cardiac risk from sexual activity in 
patients with hypertension
Sexual activity increases the risk of a cardiac event, 
because of stimulation of the sympathetic system. This may 
not be true in patients with a low absolute cardiovascular 
risk, such as controlled hypertension, with few other risk 
factors.  High-risk cardiovascular patients may have a 10-
fold increased risk of having a cardiac event during sexual 
intercourse, and for the two hours immediately after.2 Thus, 
patients with untreated, poorly controlled hypertension 
and malignant hypertension, are regarded as high-risk 
cardiovascular patients.
Conclusion
Both male and female sexual dysfunction are frequent in the 
general population.  
Essential hypertension relates to sexual dysfunction, as 
sexual dysfunction is more common in essential hypertension 
per se. A significant proportion of hypertensive patients 
experience sexual problems that impair their quality of life.
The older type of antihypertensives all negatively influence 
sexual activity, while the newer type of drugs have a neutral 
effect.
Changing the antihypertensive drug class may improve 
sexual dysfunction. 
PDE-5 inhibitors can safely be administered to hypertensives 
who are taking antihypertensive drug therapy.  Caution is 
needed with alpha-blockers. Patient who are taking nitrates 
should not be prescribed a PDE-5 inhibitor.
Erectile dysfunction per se is considered to be an 
independent predictor of cardiovascular risk, and such 
patients should be evaluated accordingly.
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